Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics reported Q1 2020 financial results with revenue of $93.2 million, up 44% year-over-year. GAAP net income rose to $30.1 million, with diluted EPS of $0.25. Non-GAAP diluted EPS was $0.34, compared to $0.20 in Q1 2019. Cash and investments increased to $349.0 million. The company maintained its 2020 revenue guidance of $355-375 million. However, COVID-19 has impacted clinical trial enrollments and timelines, but the firm anticipates ongoing developments and results from ongoing trials this year.
Summary not available.